|
1. Biologie
|
|
|
|
2. Etiologie
|
|
|
|
4.2 Dép., diag. & prono. - Génome
|
|
|
|
5. Traitements
|
|
|
|
5.12 Immunothérapies
|
|
|
|
5.12.2 Immunothérapies - CAR-T, thérapies cellulaires
|
|
|
|
5.12.4 Immunothérapies - Essais
|
|
|
|
MacroGenics halts trials of cancer drug after FDA partial hold [FierceBiotech]
|
|
|
|
|
|
MacroGenics
insists the development isn’t a big setback, pointing out that the
block only applies to recruiting new subjects, and existing patients in
both studies can continue on treatment under the assigned protocol.
Nevertheless, shares in the company fell more than 15% after hours as
investors reacted to the update.
|
|
|
|
|
|
|
|
5.12.5 Immunothérapies - Pharma
|
|
|
Gritstone ramps up bispecifics with new antibody therapeutics chief [FierceBiotech]
|
|
|
|
|
|
Gritstone’s
approach involves identifying the tumor-specific neoantigens (TSNAs) on
a patient’s tumor cells, using machine learning to determine which
candidate is most likely to activate tumor-specific T cells and then
treating the patient with personalized synthetic TSNAs. GRANITE-001 is
given in two parts—first a priming adenoviral vector, followed by
monthly boosters of an RNA vector, each containing the same 20
patient-specific TSNAs.
|
|
|
|
|
|
|
|
5.12.6 Immunothérapies - AMM
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
How to Cut Drug Prices: Experts Weigh In [NY Times]
|
|
|
|
|
|
But
if policies were adopted to reduce drug prices, could there be negative
consequences? On balance, would such policies be good or bad? I asked
three health policy experts to consider these questions in the context
of four specific drug pricing policies.
|
|
|
|
|
|
|
5.7 SABCS
|
|
|
SABCS 2018 Features Molecular Diagnostics Research [Genome Web]
|
|
|
|
|
|
They
included studies exploring the ability of breast cancer recurrence
molecular diagnostics to predict which patients are likely to experience
a relapse and benefit from chemotherapy, as well as the
cost-effectiveness of using these tools. Researchers also employed
circulating tumor DNA technologies to try to identify which patients are
likely to have a poor outcome and see their disease progress, and they
conducted whole-genome sequencing studies to track the distinct genomic
characteristics of metastatic breast cancer.
|
|
|
|
|
|
|
6.1 Observation
|
|
|
|
|
6.10 Politiques
|
|
|
Brexit 'no deal' could mean 6 months of disruption for pharma [BiopharmaDive]
|
|
|
|
|
|
"We
welcome the Secretary of State’s intention to prioritize the flow of
medicines and vaccines. But with just 16 weeks until the U.K. leaves the
EU, we need the detail. The government should take immediate action to
open up alternative supply routes between the U.K. and Europe and tell
companies so that they can make plans."
|
|
|
|
|
|
|
6.12 Ethique
|
|
|
|
6.14 Prix Nobel
|
|
|